Abcam and Genedata have expanded their collaboration to strengthen global antibody development through advanced data management, automation, and AI-enabled innovation. The initiative will deploy Genedata Biologics® across Abcam’s global R&D organization, combining Abcam’s expertise in antibody development with Genedata’s enterprise software and proprietary data model to create a unified digital foundation for scientific teams. The platform has been implemented at Abcam’s headquarters in the UK and key sites in China and the US, connecting cross-functional teams and improving consistency, visibility, and collaboration throughout the antibody development lifecycle. Genedata Biologics provides a digital backbone for Abcam’s pipeline, which delivers approximately 500 new antibodies to the market annually, while enabling researchers to manage complex workflows, track sample histories, and capture and analyze antibody characterization data within a secure, structured environment.
Also Read: Clarivate Expands Agentic AI Across Cortellis Portfolio to Accelerate Drug Development
“As researchers seek high-quality antibodies across a growing range of targets and applications, it is essential that we continue to scale and evolve our development capabilities to meet their needs,” said Kaveh Kahen, PhD, President at Abcam. “By building on Genedata’s world class platform we benefit from automation, connectivity, and flexibility needed to support our global R&D operations. Together, we have created a stronger foundation for data-driven innovation, enabling us to develop and deliver high-quality antibodies more efficiently and create greater value for customers.” Othmar Pfannes, PhD, President of Genedata, said the collaboration will help scientific teams generate actionable insights at scale and establish a foundation for AI-powered discovery, ultimately enabling researchers to access validated reagents faster.